Sulfhemoglobin under the spotlight - Detection and characterization of SHb and HbFe

Hemoglobin Human erythrocytes Molecular spectroscopy Raman spectroscopy Red blood cells Sulfhemoglobinemia

Journal

Biochimica et biophysica acta. Molecular cell research
ISSN: 1879-2596
Titre abrégé: Biochim Biophys Acta Mol Cell Res
Pays: Netherlands
ID NLM: 101731731

Informations de publication

Date de publication:
01 2023
Historique:
received: 01 07 2022
revised: 02 09 2022
accepted: 05 10 2022
pubmed: 12 10 2022
medline: 19 11 2022
entrez: 11 10 2022
Statut: ppublish

Résumé

Sulfhemoglobinemia is an incurable disease caused by an overdose of sulfur-containing drugs with oxidizing properties. Its diagnosis remains hindered due to the similarity of symptoms to other pathological state - methemoglobinemia, as well as contradictory information on the structure and characteristics of sulfhemoglobin. Herein, we present sulfhemoglobinemia model on living functional human erythrocytes, designed to recreate processes which could take place in a patient body in order to complement missing information and highlight distinctiveness of two hemoglobin (Hb) adducts formed after interaction with sulfur donors. Employed techniques, UV-Vis absorption, Raman, Fourier transformed infrared (FT-IR) and electronic circular dichroism (ECD) spectroscopies, allowed to distinguish and characterize Hb adduct with sulfur atom bounded directly to the iron ion (HbFe

Identifiants

pubmed: 36220452
pii: S0167-4889(22)00170-7
doi: 10.1016/j.bbamcr.2022.119378
pii:
doi:

Substances chimiques

Sulfhemoglobin 9010-20-2
Hemoglobins 0
Sulfur 70FD1KFU70
Porphyrins 0

Banques de données

figshare
['10.6084/m9.figshare.20029400.v1']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

119378

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Tetiana Stepanenko (T)

Jagiellonian University, Faculty of Chemistry, 2 Gronostajowa Str., 30-387 Krakow, Poland; Jagiellonian University, Jagiellonian Centre for Experimental Therapeutics (JCET), 14 Bobrzyńskiego Str., 30-348 Krakow, Poland.

Grzegorz Zając (G)

Jagiellonian University, Jagiellonian Centre for Experimental Therapeutics (JCET), 14 Bobrzyńskiego Str., 30-348 Krakow, Poland.

Artur Czajkowski (A)

Jagiellonian University, Faculty of Biochemistry, Biophysics and Biotechnology (BBB), 7 Gronostajowa Str., 30-387 Krakow, Poland.

Wiktoria Rutkowska (W)

Jagiellonian University, Faculty of Chemistry, 2 Gronostajowa Str., 30-387 Krakow, Poland.

Andrzej Górecki (A)

Jagiellonian University, Faculty of Biochemistry, Biophysics and Biotechnology (BBB), 7 Gronostajowa Str., 30-387 Krakow, Poland.

Katarzyna Maria Marzec (KM)

Lukasiewicz Research Network - Krakow Institute of Technology, 73 Zakopianska St., 30-418 Krakow, Poland.

Jakub Dybas (J)

Jagiellonian University, Jagiellonian Centre for Experimental Therapeutics (JCET), 14 Bobrzyńskiego Str., 30-348 Krakow, Poland. Electronic address: jakub.dybas@uj.edu.pl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH